Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P888: MATCHED-ADJUSTED INDIREC...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Bibliographic Details
Main Authors: Ajai Chari, Joris Diels, Suzy Van Sanden, Lixia Pei, Eric Ammann, Christoph Heuck, Colleen Kane, Anil Londhe, Steve Peterson, Donna Reece
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000970456.81043.cc
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000970456.81043.cc

Similar Items

  • Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
    by: Neupane K, et al.
    Published: (2021-07-01)
  • Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
    by: Joseph NS, et al.
    Published: (2021-08-01)
  • P893: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS PHYSICIAN’S CHOICE THERAPY IN TRIPLE-CLASS EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHED COHORT ANALYSIS
    by: Albert Oriol, et al.
    Published: (2023-08-01)
  • Corneal epithelial changes in a patient treated with belantamab mafodotin
    by: Leandro Inferrera, et al.
    Published: (2023-01-01)
  • The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
    by: Melody R. Becnel, et al.
    Published: (2020-12-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs